FDA clears Ensoma's trial of in vivo blood stem cell editing therapy for X-linked chronic granulomatous disease, following China's Yoltech earlier this year.

The China Plus One strategy has been playing out quietly for some time now. With Trump set to take over, it is likely he will reignite the tariff wars, further pushing China Plus One on the ground and ...

Losing fat from the butt is a common fitness goal. However, it is not possible to spot-reduce fat in a specific area. Reducing overall weight, running, squats, and other exercises can also help ...

The PRV Time and PRV Flow allow for precise control of pressure and optimization of water network performance. The Geonor M-600 algorithm supports direct integration with the Geonor precipitation ...

64th AGM Notice and Annual Report for the FY 2023-24 of the Company pursuant to Regulation 34 of the SEBI (LODR) Regulations, 2015. Hindusthan Urban Infrastructure Notice Of The 64Th Annual General ...

If approved in the U.S., the therapy may be eligible for a Rare Pediatric Disease Priority Review Voucher (PRV). Dordaviprone ... merger of Pinetree Acquisition Sub, Inc., a Delaware corporation ...

If approved in the U.S., the therapy may be eligible for a Rare Pediatric Disease Priority Review Voucher (PRV). Dordaviprone is also being studied in the ongoing Phase 3 ACTION trial to evaluate ...